Galera Therapeutics Inc. (GRTX) NASDAQ

$1.29 -0.05 (-3.73%)

Market Cap: $35.43M

As of 11/30/21 10:19 AM EST. Market open.

(GRTX)

Galera Therapeutics Inc. (GRTX) NASDAQ

$1.29 -0.05 (-3.73%)

Market Cap: $35.43M

As of 11/30/21 10:19 AM EST. Market open.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a highly selective small molecule superoxide dismutase (SOD) mimetic initially ... read more

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera's second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
38
Address
.
KEY STATS
Open
$1.29
Previous Close
$1.34
Days Range
$1.33 - $1.53
52 week range
$1.33 - $12.99
Volume
330,911
Avg. Volume (30 days)
1,958,132
Market Cap
$35.43M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
26,438,767
Open
$1.29
Previous Close
$1.34
Days Range
$1.33 - $1.53
52 week range
$1.33 - $12.99
Volume
330,911
Avg. Volume (30 days)
1,958,132
Market Cap
$35.43M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
26,438,767

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR GALERA THERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
HOLMLUND JON T Chief Medical Officer Sep 01, 2021 Option Exercise $2.43 47,756 116,047 47,756 Sep 03, 2021, 04:31 PM
HOLMLUND JON T Chief Medical Officer Sep 01, 2021 Sale $8.47 47,756 404,498 0 Sep 03, 2021, 04:31 PM
West Linda Director Jun 15, 2021 Buy $9.13 10,000 91,300 40,000 Jun 17, 2021, 06:41 PM
Alleva Lawrence M Director Jun 01, 2021 Buy $8.59 4,045 34,741 4,045 Jun 03, 2021, 05:22 PM
West Linda Director Jun 01, 2021 Buy $8.64 10,000 86,381 20,000 Jun 02, 2021, 05:35 PM
West Linda Director May 28, 2021 Buy $8.64 10,000 86,410 10,000 Jun 02, 2021, 05:35 PM
Sorensen Mel President and CEO Mar 26, 2021 Option Exercise $1.09 217,015 235,492 232,044 Mar 30, 2021, 04:42 PM
Novo Holdings A/S 10% Owner Feb 18, 2021 Sale $10.58 500,000 5,290,000 2,459,021 Feb 19, 2021, 05:20 PM
Alleva Lawrence M Director Nov 13, 2020 Buy $10.22 2,325 23,771 6,325 Nov 17, 2020, 04:06 PM
Sussman Joel F. Chief Accounting Officer Nov 12, 2020 Option Exercise $1.07 10,000 10,700 10,000 Nov 16, 2020, 07:46 PM
Sussman Joel F. Chief Accounting Officer Nov 13, 2020 Option Exercise $1.46 10,000 14,552 10,000 Nov 16, 2020, 07:46 PM
Sussman Joel F. Chief Accounting Officer Nov 13, 2020 Sale $10.32 10,000 103,197 0 Nov 16, 2020, 07:46 PM
Sussman Joel F. Chief Accounting Officer Nov 12, 2020 Sale $10.06 10,000 100,627 0 Nov 16, 2020, 07:46 PM
HOLMLUND JON T Chief Medical Officer Oct 26, 2020 Option Exercise $2.43 2,244 5,453 2,244 Oct 28, 2020, 05:56 PM
HOLMLUND JON T Chief Medical Officer Oct 26, 2020 Sale $15.00 2,244 33,660 0 Oct 28, 2020, 05:56 PM
Novo Holdings A/S 10% Owner Oct 15, 2020 Sale $11.00 450,000 4,950,000 2,959,021 Oct 19, 2020, 04:34 PM
HOLMLUND JON T Chief Medical Officer Oct 06, 2020 Option Exercise $1.11 10,536 11,668 5,632 Oct 07, 2020, 05:01 PM
HOLMLUND JON T Chief Medical Officer Oct 05, 2020 Option Exercise $1.07 100 107 100 Oct 07, 2020, 05:01 PM
HOLMLUND JON T Chief Medical Officer Oct 06, 2020 Sale $12.00 10,536 126,432 0 Oct 07, 2020, 05:01 PM
HOLMLUND JON T Chief Medical Officer Oct 05, 2020 Sale $12.00 100 1,200 0 Oct 07, 2020, 05:01 PM
Novartis Bioventures Ltd Former 10% Owner Jun 19, 2020 Sale $8.25 1,001,312 8,260,824 2,467,961 Jun 22, 2020, 04:52 PM
Novartis Bioventures Ltd Former 10% Owner Jun 18, 2020 Sale $9.04 900 8,136 3,469,273 Jun 22, 2020, 04:52 PM
Novartis Bioventures Ltd 10% Owner Jun 15, 2020 Sale $9.05 6,164 55,784 3,483,395 Jun 17, 2020, 05:47 PM
Novartis Bioventures Ltd 10% Owner Jun 17, 2020 Sale $9.27 4,622 42,846 3,470,173 Jun 17, 2020, 05:47 PM
Novartis Bioventures Ltd 10% Owner Jun 16, 2020 Sale $9.30 8,600 79,980 3,474,795 Jun 17, 2020, 05:47 PM
Novartis Bioventures Ltd 10% Owner Jun 12, 2020 Sale $9.19 1,500 13,785 3,489,559 Jun 12, 2020, 06:33 PM
Novartis Bioventures Ltd 10% Owner Jun 11, 2020 Sale $9.21 7,200 66,312 3,491,059 Jun 12, 2020, 06:33 PM
Novartis Bioventures Ltd 10% Owner Jun 10, 2020 Sale $9.46 8,532 80,713 3,498,259 Jun 12, 2020, 06:33 PM
Novartis Bioventures Ltd 10% Owner Jun 09, 2020 Sale $9.38 7,000 65,660 3,506,791 Jun 09, 2020, 08:02 PM
Novartis Bioventures Ltd 10% Owner Jun 08, 2020 Sale $9.66 5,659 54,666 3,513,791 Jun 09, 2020, 08:02 PM
Novartis Bioventures Ltd 10% Owner Jun 05, 2020 Sale $9.66 8,652 83,578 3,519,450 Jun 09, 2020, 08:02 PM
Novartis Bioventures Ltd 10% Owner Jun 03, 2020 Sale $9.78 5,208 50,934 3,532,190 Jun 04, 2020, 05:36 PM
Novartis Bioventures Ltd 10% Owner Jun 02, 2020 Sale $9.68 5,669 54,876 3,537,398 Jun 04, 2020, 05:36 PM
Novartis Bioventures Ltd 10% Owner Jun 04, 2020 Sale $9.55 4,088 39,040 3,528,102 Jun 04, 2020, 05:36 PM
HOLMLUND JON T Chief Medical Officer May 26, 2020 Option Exercise $1.07 692 740 692 May 28, 2020, 04:50 PM
HOLMLUND JON T Chief Medical Officer May 26, 2020 Sale $12.00 692 8,304 0 May 28, 2020, 04:50 PM
HOLMLUND JON T Chief Medical Officer May 21, 2020 Option Exercise $1.07 1,174 1,256 1,174 May 22, 2020, 05:20 PM
HOLMLUND JON T Chief Medical Officer May 20, 2020 Option Exercise $1.07 969 1,037 969 May 22, 2020, 05:20 PM
HOLMLUND JON T Chief Medical Officer May 21, 2020 Sale $12.00 1,174 14,088 0 May 22, 2020, 05:20 PM
HOLMLUND JON T Chief Medical Officer May 20, 2020 Sale $12.00 969 11,628 0 May 22, 2020, 05:20 PM
HOLMLUND JON T Chief Medical Officer May 08, 2020 Option Exercise $1.07 5,102 5,459 5,102 May 12, 2020, 07:00 PM
HOLMLUND JON T Chief Medical Officer May 12, 2020 Option Exercise $1.07 671 718 671 May 12, 2020, 07:00 PM
HOLMLUND JON T Chief Medical Officer May 11, 2020 Option Exercise $1.07 185 198 185 May 12, 2020, 07:00 PM
HOLMLUND JON T Chief Medical Officer May 08, 2020 Sale $12.00 5,102 61,224 0 May 12, 2020, 07:00 PM
HOLMLUND JON T Chief Medical Officer May 12, 2020 Sale $12.00 671 8,052 0 May 12, 2020, 07:00 PM
HOLMLUND JON T Chief Medical Officer May 11, 2020 Sale $12.00 185 2,220 0 May 12, 2020, 07:00 PM
HOLMLUND JON T Chief Medical Officer May 06, 2020 Option Exercise $1.07 1,489 1,593 1,489 May 07, 2020, 07:12 PM
HOLMLUND JON T Chief Medical Officer May 05, 2020 Option Exercise $1.07 3,064 3,278 3,064 May 07, 2020, 07:12 PM
HOLMLUND JON T Chief Medical Officer May 07, 2020 Option Exercise $1.07 2,059 2,203 2,059 May 07, 2020, 07:12 PM
HOLMLUND JON T Chief Medical Officer May 06, 2020 Sale $12.00 1,489 17,868 0 May 07, 2020, 07:12 PM
HOLMLUND JON T Chief Medical Officer May 05, 2020 Sale $12.16 3,064 37,258 0 May 07, 2020, 07:12 PM
HOLMLUND JON T Chief Medical Officer May 07, 2020 Sale $12.00 2,059 24,709 0 May 07, 2020, 07:12 PM
Alleva Lawrence M Director Dec 13, 2019 Buy $9.78 4,000 39,139 4,000 Dec 17, 2019, 04:05 PM
Clarus IV-A, L.P. 10% Owner Nov 12, 2019 Buy $12.00 250,000 3,000,000 652,324 Nov 14, 2019, 05:00 PM
Blackstone Clarus GP L.P. 10% Owner Nov 12, 2019 Buy $12.00 250,000 3,000,000 652,324 Nov 14, 2019, 05:00 PM
Novo Holdings A/S 10% Owner Nov 12, 2019 Buy $12.00 500,000 6,000,000 3,409,021 Nov 14, 2019, 02:16 PM
New Enterprise Associates 14, L.P. 10% Owner Nov 12, 2019 Buy $12.00 416,666 4,999,992 4,358,047 Nov 12, 2019, 05:00 PM
Sofinnova Venture Partners IX, L.P. 10% Owner Nov 12, 2019 Buy $12.00 750,000 9,000,000 3,083,712 Nov 12, 2019, 04:17 PM
Novartis Bioventures Ltd 10% Owner Nov 12, 2019 Buy $12.00 250,000 3,000,000 3,543,067 Nov 12, 2019, 04:15 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
HOLMLUND JON T Chief Medical Officer 09/01/2021 116,047
HOLMLUND JON T Chief Medical Officer 09/01/2021 404,498
West Linda Director 06/15/2021 91,300
Alleva Lawrence M Director 06/01/2021 34,741
West Linda Director 06/01/2021 86,381
West Linda Director 05/28/2021 86,410
Sorensen Mel President and CEO 03/26/2021 235,492
Novo Holdings A/S 10% Owner 02/18/2021 5,290,000
Alleva Lawrence M Director 11/13/2020 23,771
Sussman Joel F. Chief Accounting Officer 11/12/2020 10,700
Sussman Joel F. Chief Accounting Officer 11/13/2020 14,552
Sussman Joel F. Chief Accounting Officer 11/13/2020 103,197
Sussman Joel F. Chief Accounting Officer 11/12/2020 100,627
HOLMLUND JON T Chief Medical Officer 10/26/2020 5,453
HOLMLUND JON T Chief Medical Officer 10/26/2020 33,660
Novo Holdings A/S 10% Owner 10/15/2020 4,950,000
HOLMLUND JON T Chief Medical Officer 10/06/2020 11,668
HOLMLUND JON T Chief Medical Officer 10/05/2020 107
HOLMLUND JON T Chief Medical Officer 10/06/2020 126,432
HOLMLUND JON T Chief Medical Officer 10/05/2020 1,200
Novartis Bioventures Ltd Former 10% Owner 06/19/2020 8,260,824
Novartis Bioventures Ltd Former 10% Owner 06/18/2020 8,136
Novartis Bioventures Ltd 10% Owner 06/15/2020 55,784
Novartis Bioventures Ltd 10% Owner 06/17/2020 42,846
Novartis Bioventures Ltd 10% Owner 06/16/2020 79,980
Novartis Bioventures Ltd 10% Owner 06/12/2020 13,785
Novartis Bioventures Ltd 10% Owner 06/11/2020 66,312
Novartis Bioventures Ltd 10% Owner 06/10/2020 80,713
Novartis Bioventures Ltd 10% Owner 06/09/2020 65,660
Novartis Bioventures Ltd 10% Owner 06/08/2020 54,666
Novartis Bioventures Ltd 10% Owner 06/05/2020 83,578
Novartis Bioventures Ltd 10% Owner 06/03/2020 50,934
Novartis Bioventures Ltd 10% Owner 06/02/2020 54,876
Novartis Bioventures Ltd 10% Owner 06/04/2020 39,040
HOLMLUND JON T Chief Medical Officer 05/26/2020 740
HOLMLUND JON T Chief Medical Officer 05/26/2020 8,304
HOLMLUND JON T Chief Medical Officer 05/21/2020 1,256
HOLMLUND JON T Chief Medical Officer 05/20/2020 1,037
HOLMLUND JON T Chief Medical Officer 05/21/2020 14,088
HOLMLUND JON T Chief Medical Officer 05/20/2020 11,628
HOLMLUND JON T Chief Medical Officer 05/08/2020 5,459
HOLMLUND JON T Chief Medical Officer 05/12/2020 718
HOLMLUND JON T Chief Medical Officer 05/11/2020 198
HOLMLUND JON T Chief Medical Officer 05/08/2020 61,224
HOLMLUND JON T Chief Medical Officer 05/12/2020 8,052
HOLMLUND JON T Chief Medical Officer 05/11/2020 2,220
HOLMLUND JON T Chief Medical Officer 05/06/2020 1,593
HOLMLUND JON T Chief Medical Officer 05/05/2020 3,278
HOLMLUND JON T Chief Medical Officer 05/07/2020 2,203
HOLMLUND JON T Chief Medical Officer 05/06/2020 17,868
HOLMLUND JON T Chief Medical Officer 05/05/2020 37,258
HOLMLUND JON T Chief Medical Officer 05/07/2020 24,709
Alleva Lawrence M Director 12/13/2019 39,139
Clarus IV-A, L.P. 10% Owner 11/12/2019 3,000,000
Blackstone Clarus GP L.P. 10% Owner 11/12/2019 3,000,000
Novo Holdings A/S 10% Owner 11/12/2019 6,000,000
New Enterprise Associates 14, L.P. 10% Owner 11/12/2019 4,999,992
Sofinnova Venture Partners IX, L.P. 10% Owner 11/12/2019 9,000,000
Novartis Bioventures Ltd 10% Owner 11/12/2019 3,000,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2021
06/30/2021
1.48%
1Q
09/30/2021
03/31/2021
2.33%
2Q
09/30/2021
12/31/2020
2.81%
3Q
09/30/2021
09/30/2020
2.93%
4Q
09/30/2021
06/30/2020
3.00%
5Q
09/30/2021
03/31/2020
3.04%
6Q
Load More

Period of Report: 09/30/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2021
1.48%
1Q
03/31/2021
2.33%
2Q
12/31/2020
2.81%
3Q
09/30/2020
2.93%
4Q
06/30/2020
3.00%
5Q
03/31/2020
3.04%
6Q
Load More